KLRS

Kalaris is a clinical-stage biopharma with zero product revenue (the $165K 'revenue' is a stale FY2019 figure, making the 585x P/S meaningless) and a single lead asset, TH103, an intravitreal anti-VEGF for wet AMD. Everything rides on one program: the company reported positive initial Phase 1a SAD data in December 2025 and is now running a Phase 1b/2 dose-finding study in ~60–80 nAMD patients. This is the result of a March 2025 reverse merger into the former AlloVir shell, which is why shares ballooned +354.6% to 22.9M and total assets jumped ~19x — the entity as currently constituted has almost no operating history to underwrite.

The one genuinely attractive feature is the balance sheet relative to price. The 10-K reports $118.0M of cash and short-term marketable securities against a $96.6M market cap — the stock trades below net cash, with $5.15/share of cash+securities versus a $4.21 quote. Current assets ($119M) dwarf current liabilities ($9.71M), liabilities/equity is a conservative 0.54x, and the $50M December 2025 private placement just refilled the tank. Operating cash burn of ~$38.4M/year against that cash implies roughly 2.5–3 years of runway — enough to reach a real Phase 1b/2 data readout. The narrowing net loss ($43.4M vs $69.2M) and 31.7% drop in R&D reflect post-merger rationalization, not a deteriorating business.